Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Forbion taps Dyne vet Brumm to guide growing U.S. presence

Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona

June 28, 2024 1:03 AM UTC

In a bid to grow its U.S. footprint, Forbion hired Josh Brumm as general partner and unveiled plans for a new office in the U.S. in Boston. Brumm, who will be located at the European VC’s new Boston address, was most recently president and CEO of muscle disease company Dyne Therapeutics Inc. (NASDAQ:DYN), a Forbion portfolio company. Forbion said Brumm will hunt for new opportunities in North America and Europe and support existing portfolio companies, including those “working towards U.S. expansion.”

Edward Dulac will become EVP, CFO at Intellia Therapeutics Inc. (NASDAQ:NTLA) on July 22, succeeding Glenn Goddard, who is stepping down June 30. Dulac was CFO at Fate Therapeutics Inc. (NASDAQ:FATE), before which he held several roles at Celgene Corp. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article